Evaluation of 177Lu-Psma-617 SPECT/CT Quantitation As a Response Biomarker Within a Prospective 177Lu-Psma-617 and NOX66 Combination Trial (Lupin).
JOURNAL OF NUCLEAR MEDICINE（2023）
Key words
metastatic prostate cancer,SPECT,lutetium-PSMA,response biomarker
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined